BiotechTube

Bendamustine Hydrochloride + Isatuximab

Phase 2Withdrawn
1 views this week 0 watching💤 Quiet
Interest: 27/100
27
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Amyloidosis

Conditions

Amyloidosis, Light Chain (AL) Amyloidosis

Trial Timeline

Sep 1, 2022 → Jan 1, 2026

NCT ID
NCT04943302

About Bendamustine Hydrochloride + Isatuximab

Bendamustine Hydrochloride + Isatuximab is a phase 2 stage product being developed by Sanofi for Amyloidosis. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT04943302. Target conditions include Amyloidosis, Light Chain (AL) Amyloidosis.

What happened to similar drugs?

0 of 12 similar drugs in Amyloidosis were approved

Approved (0) Terminated (2) Active (10)
🔄NTLA-2001 + PlaceboRegeneron PharmaceuticalsPhase 3
🔄PatisiranAlnylam PharmaceuticalsPhase 3
🔄PatisiranAlnylam PharmaceuticalsPhase 3
🔄Nucresiran + Sterile Normal Saline (0.9% NaCl)Alnylam PharmaceuticalsPhase 3
🔄Vutrisiran + Sterile Normal Saline (0.9% NaCl)Alnylam PharmaceuticalsPhase 3
🔄Placebo + PatisiranAlnylam PharmaceuticalsPhase 3
🔄patisiran (ALN-TTR02) + Sterile Normal Saline (0.9% NaCl)Alnylam PharmaceuticalsPhase 3

Hype Score Breakdown

Clinical
12
Activity
0
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT04943302Phase 2Withdrawn

Competing Products

20 competing products in Amyloidosis

See all competitors
ProductCompanyStageHype Score
ZN-d5Zentalis PharmaceuticalsPhase 1/2
22
VELCADEJohnson & JohnsonPhase 1/2
32
ABBV-383 (Etentamig)AbbViePhase 1/2
39
Venetoclax + Dexamethasone + DaratumumabAbbViePhase 1/2
24
Eplontersen Solution for InjectionAstraZenecaPhase 1
29
Treatment of transthyretin (ATTR) amyloidosis in observational study settingAstraZenecaPre-clinical
33
Carfilzomib + DexamethasoneAmgenPhase 1
29
IdelalisibGilead SciencesPhase 2
27
TafamidisPfizerPre-clinical
26
TafamidisPfizerPre-clinical
30
Fx-1006APfizerPhase 2
35
tafamidisPfizerPre-clinical
26
Cyclophosphamide + Dexamethasone + Elotuzumab + LenalidomideBristol Myers SquibbPhase 2
31
IsatuximabBristol Myers SquibbPhase 2
42
Bortezomib + Cyclophosphamide + Dexamethasone + IsatuximabSanofiPhase 1
33
NC-503 (Anti-amyloidotic (AA) Agent)GSK plcPhase 2/3
38
NTLA-2001 + PlaceboRegeneron PharmaceuticalsPhase 3
44
LinvoseltamabRegeneron PharmaceuticalsPhase 1/2
39
ALN-TTR01 + Sterile Normal Saline (0.9% NaCl)Alnylam PharmaceuticalsPhase 1
26
PatisiranAlnylam PharmaceuticalsPhase 3
37